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Background. As part of the Household Influenza Vaccine Evaluation (HIVE) study, acute respiratory infections (ARI) have been 
identified in children and adults from 2010 to 2018.
Methods. Annually, 890 to 1441 individuals were followed and contacted weekly to report ARIs. Specimens collected during 
illness were tested for human coronaviruses (HCoV) types OC43, 229E, HKU1, and NL63.
Results. In total, 993 HCoV infections were identified during the 8 years, with OC43 most commonly seen and 229E the least. 
HCoVs were detected in a limited time period, between December and April/May and peaked in January/February. Highest infec-
tion frequency was in children <5 years (18 per 100 person-years), with little variation in older age groups (range, 7 to 11 per 100 
person-years). Overall, 9% of adult cases and 20% of cases in children were associated with medical consultation. Of the 993 infec-
tions, 260 were acquired from an infected household contact. The serial interval between index and household-acquired cases ranged 
from 3.2 to 3.6 days and the secondary infection risk ranged from 7.2% to 12.6% by type.
Conclusions. Coronaviruses are sharply seasonal. They appear, based on serial interval and secondary infection risk, to have 
similar transmission potential to influenza A(H3N2) in the same population.
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Coronaviruses, long known to infect a wide variety of species, 
have been recognized as human respiratory pathogens for more 
than 60  years [1–3]. While animal coronaviruses have been as-
sociated with severe disease in their respective hosts, human cor-
onaviruses (HCoV) were historically detected in mild respiratory 
illnesses [4–6]. Therefore, the identification of severe acute respira-
tory syndrome (SARS) as caused by a coronavirus of animal origin 
in 2002 was a surprise because of its epidemic behavior as well as 
its severity [7, 8]. Also a surprise was the ultimate interruption of 
SARS transmission by public health measures [9]. In 2012, another 
novel coronavirus of animal origin emerged as the causative agent 
of Middle East respiratory syndrome (MERS) [10]. Unlike SARS, 
human-to-human transmission of MERS has been limited and 
sporadic cases have continued to occur, primarily in Saudi Arabia 
among those with contact with camels [11]. The current outbreak 
of a novel coronavirus (SARS-CoV-2) has focused attention back 
to this often forgotten and little studied group of pathogens [12].
HCoVs were first recognized when specimens from indi-
viduals ill with respiratory illnesses were inoculated into organ 
cultures. One of these viruses is now known as OC (organ cul-
ture) 43 [13]. Another virus, 229E was first grown in primary 
human kidney culture [14]. Because of the difficulties in iso-
lating them, much of the initial work in understanding their oc-
currence in was done by serology [15, 16]. Following renewed 
interest after the SARS epidemic, 2 additional coronaviruses, 
HKU1 and NL63, were identified in the 2000s, initially from 
persons with severe respiratory illnesses [17–20].
Availability of reverse-transcriptase polymerase chain re-
action (RT-PCR) has now made it possible to detect infection 
easily for each of the 4 known human coronaviruses. However, 
as data from population-based studies using molecular methods 
have accumulated, minimal attention has been paid to these 
viruses, perhaps because there was so little known about their 
role in respiratory illnesses. The Household Influenza Vaccine 
Evaluation (HIVE) study is a longitudinal investigation of res-
piratory illnesses in households with children in the Ann Arbor, 
Michigan area that has been ongoing since 2010. Here we report 
on the occurrence of the 4 HCoV types over an 8-year period.
METHODS
Study Population
The complete methods of the HIVE cohort have been published 
previously [21]. Households were recruited from local house-
holds receiving primary care from the University of Michigan 
Health Care System. From 2010–2011 through 2015–2016, 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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eligible households were those with 4 or more members at least 
2 of whom were younger than 18  years. In subsequent years, 
eligible households contained 3 or more members including at 
least 1 child younger than 5 years (2016–2017) or younger than 
10 years (2017–2018). Each year in the spring or summer, house-
holds attended an enrollment or reengagement visit to collect 
or update the demographic characteristics for each participant 
and household. Adult household members provided informed 
consent for themselves and their children, and children 7 years 
or older also provided verbal assent prior to participating. This 
study was reviewed and approved by the institutional review 
board at the University of Michigan Medical School.
Acute Respiratory Illness Surveillance
HIVE participants were instructed to report the onset of 2 or 
more acute respiratory illness (ARI) symptoms in anyone in the 
household, including: cough, fever or feverishness, nasal conges-
tion, chills, headache, body aches, and sore throat. Weekly email 
and phone contacts were used to confirm the presence or absence 
of ARI in the household. Beginning in 2014–2015, a separate 
set of age-specific symptom qualifiers were provided for parti-
cipants younger than 3  years, including: cough, fever or fever-
ishness, nasal congestion, trouble breathing, fussiness, decreased 
appetite, and fatigue. Ill participants with 2 or more of the above 
symptoms attended an illness visit within 7 days of illness onset 
where study staff interviewed them about their illness and col-
lected nasal and throat swabs (nasal only in children <3 years) 
combined in a single vial of viral transport media. Study staff 
followed-up with ill participants approximately a week after their 
illness visit to collect additional information about the course of 
the illness, including participants’ reports of whether they con-
tacted a health care provider regarding their illness.
Prior to the 2014–2015 season, HIVE ARI surveillance 
periods were seasonal based on the likely influenza season. For 
the first 4 study years, the annual surveillance periods were 1 
October 2010 through 30 April 2011, 1 December 2011 through 
10 May 2012, 1 October 2012 through 13 May 2013, and 1 
October 2013 through 30 April 2014. Surveillance resumed on 
1 October 2014 and has been operating year round since then. 
New surveillance years are designated beginning 1 July and 
lasting until 30 June of the subsequent year.
Laboratory Testing
Respiratory specimens collected at illness visits were tested for 
detection of respiratory viruses, including the 4 seasonal coro-
navirus types (229E, OC43, HKU1, and NL63). For specimens 
collected prior to the 2016–2017 study year, testing was per-
formed by singleplex RT-PCR using primers and probes devel-
oped by the CDC Division of Viral Diseases, Gastroenteritis, and 
Respiratory Viruses [22]. Specimens collected in the 2016–2017 
and 2017–2018  years were tested using the FTD Respiratory 
Pathogen 33 multiplex PCR kit (Fast Track Diagnostics).
Statistical Analysis
Seasonal case counts of HCoV 229E, HKU1, NL63, and OC43 
were used to assess annual patterning of each type; counts were 
also summed by month across all seasons combined to assess 
broad seasonality by type. Illnesses with multiple, coincident 
HCoV detections were only counted once in analyses of overall 
HCoV infections, but each HCoV type involved in coincident 
detection was also included in type-specific analyses.
Type-specific coronavirus incidence and corresponding 95% 
confidence intervals (CI) were calculated by age group (<5, 6–11, 
12–17, 18–49, and ≥50 years) and by study year. Incidence was 
calculated as the number of type-specific coronavirus infections 
divided by the total participant time included during a specified 
time period. Because the majority of the HCoV season was cap-
tured even in study years without year-round surveillance, all 
participants were treated as contributing a full year of person 
time for each study year in which they were enrolled.
For each study year, we defined household index cases as the 
first person in a household to develop ARI with HCoV detection. 
Secondary cases were defined as those who developed ARI with 
HCoV detection within 14 days following illness in a household 
contact with the same type. The serial interval was calculated as 
the average number of days from the illness onset in a household 
index case to the illness onset in secondary cases. Secondary 
infection risks were calculated as the proportion of household 
contacts exposed to an index case who developed secondary in-
fection. For the purpose of these transmission analyses, only the 
first introduction of HCoV to a household was considered.
We used latent class analysis to identify and compare classes 
of illness severity of HCoV infection across age groups and the 
4 HCoV types (Supplementary Materials). For the latent items, 
we identified 7 participant-reported potential markers of ill-
ness severity including illness symptoms (cough, fever, fatigue, 
wheezing, and dyspnea), missed work or school, and medically 
attended illness (phone consultation, outpatient care, and inpa-
tient care). A priori, we anticipated 3 latent classes of severity 
to represent mild, moderate, and severe illness; model diagnos-
tics also confirmed that a 3-class model was most parsimonious. 
Latent class groups were then assigned to each HCoV infection, 
not including cases with multiple coincident HCoV types de-
tected. Age-adjusted multinomial logistic regression models 
were then used to compare the odds of being assigned to each 
latent class between the 4 HCoV types.
RESULTS
Characteristics of the Study Population
The number of individuals under study ranged from 895 to 
1441, and the number of households ranged from 209 to 340 
over the 8  years (Table  1). Because of the requirement that 
children be present in the household, the studied population 
tended to be young, with relative absence of older adults. The 
numbers in the cohort varied from year to year but the age 
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/article-abstract/222/1/9/5815743 by guest on 05 August 2020
Coronavirus Occurrence and Transmission • jid 2020:222 (1 july) • 11
structure remained similar in all years, due to combined reten-
tion of existing households and recruitment of new households 
with young children.
The number of ARIs reported also varied from year to year, 
mainly related to the number of individuals on report but also 
the differential occurrence of influenza and other respiratory 
viruses (Table 1). Overall, from 2010–2011 through 2017–2018, 
7992 ARI cases were reported to HIVE; 7469 (93%) had an 
illness visit with specimen collection and were tested for res-
piratory virus detection. The proportion of ARIs associated 
with coronavirus identification varied between 8.3% during 
the major influenza year 2014–2015 to 16.3% in 2012–2013. 
Codetection of multiple coronavirus types ranged from 0.7% of 
all coronavirus ARIs in 2010–2011 to 14.2% in 2014–2015.
Variation in Identifying the 4 Coronaviruses by Seasons and Years
There was distinct seasonality in the identifications of the viruses. 
In the first 5 of the 8 years, no surveillance was conducted from 
June to September. When year-round surveillance was in place 
in the 2015–2016 through 2017–2018 study years, only 9 (2.5%) 
of the total 364 coronavirus-associated ARI occurred from June 
through September. Combined over the 8 years, the number of 
identifications for each virus increased in December, peaked in 
January or February, and began to decrease in March (Figure 1). 
The seasonal similarity between the 4 types is striking, with only 
the peak aggregate month differing between January and February.
Identification of each of the 4 coronaviruses types occurred in 
each of the 8 study years, except for 2016–2017 when no HKU1 
viruses were identified (Table  1 and Figure  2). In prior com-
munity studies [16, 23–25], there were suggestions of a cycling 
between 229E and OC43, with major years followed by lesser 
years. Such a pattern appears to be present for all types where 
relatively high incidence is not seen in consecutive years for 
a specific type. Likewise, combinations of cocirculating types 
were not found to be consistent from year to year.
Occurrence of Infections by Age
Infection rates for common respiratory pathogens are highest in 
young children and usually fall off with increasing age. With the 
exception of 229E, where incidence per 100 person-years was 
relatively low and did not vary by age, the incidence was consist-
ently highest among children younger than 5 years (Figure 3). 
Among those older than 5  years, incidence was relatively flat 
with little consistent variation with increase in age.
Illness Severity and Outcomes
Overall, 9% of adult cases and 20% of cases in children were as-
sociated with medical consultation. However, medical consul-
tation only captures 1 facet of overall illness severity. Therefore, 
we used latent class analysis to categorize coronavirus case 
severity based on participant-reported symptoms and ac-
tions taken during the course of their illness (Supplementary 
Materials). Mild illnesses were primarily characterized by 
cough and fatigue, those with moderate illnesses were addition-
ally likely to have fever and to miss school or work, and those 
with severe illness additionally were likely to have wheezing, 
dyspnea, or to seek care for their illness. Of all single corona-
virus detections, 59% were categorized as mild illness by latent 
class methods. Moderate and severe illness were noted in 31% 
and 10% of coronavirus detections, respectively. HCoV illnesses 
Table 1. Characteristics of the Study Population and Counts of Human Coronavirus Infections by Study Year: Household Influenza Vaccine Evaluation 
(HIVE) Cohort 2010–2018
 Characteristic
Season
2010–2011 2011–2012 2012–2013 2013–2014 2014–2015 2015–2016 2016–2017 2017–2018
Surveillance period 1 Oct–30 Apr 1 Dec–10 May 1 Oct–13 May 1 Oct–30 Apr 1 Oct–30 Jun 1 Jul–30 Jun 1 Jul–30 Jun 1 Jul–30 Jun
Households enrolled, No. 328 213 321 232 340 227 209 293
Participants enrolled, No. 1441 943 1426 1049 1431 996 895 1189
Age groups, y, No. (%)         
 0–5 250 (17.4) 131 (13.9) 225 (15.8) 133 (12.7) 205 (14.3) 97 (9.7) 117 (13.1) 220 (18.5)
 6–11 382 (26.5) 278 (29.5) 401 (28.1) 316 (30.1) 445 (31.1) 327 (32.8) 257 (28.7) 298 (25.1)
 12–17 208 (14.4) 141 (15.0) 208 (14.6) 169 (16.1) 212 (14.8) 173 (17.4) 150 (16.8) 166 (14.0)
 18–49 546 (37.9) 353 (37.4) 536 (37.6) 385 (36.7) 512 (35.8) 351 (35.2) 332 (37.1) 457 (38.4)
 ≥50 55 (3.8) 40 (4.2) 56 (3.9) 46 (4.4) 57 (4.0) 48 (4.8) 39 (4.4) 48 (4.0)
ARI reports, No. 1028 417 1227 706 1362 934 847 1401
HCoV-positive cases, No.  
(% of all ARI cases)
        
 All typesa 152 (14.8) 59 (14.1) 200 (16.3) 105 (14.9) 113 (8.3) 109 (11.7) 112 (13.2) 143 (10.2)
 229E 7 (0.7) 20 (4.8) 8 (0.7) 45 (6.4) 8 (0.6) 3 (0.3) 46 (5.4) 12 (0.9)
 HKU1 28 (2.7) 19 (4.6) 17 (1.4) 30 (4.2) 14 (1) 36 (3.9) 0 (0) 49 (3.5)
 NL63 62 (6) 14 (3.4) 75 (6.1) 21 (3) 37 (2.7) 40 (4.3) 11 (1.3) 63 (4.5)
 OC43 56 (5.4) 13 (3.1) 113 (9.2) 16 (2.3) 71 (5.2) 34 (3.6) 58 (6.8) 26 (1.9)
Abbreviations: ARI, acute respiratory infections; HCoV, human coronavirus.
aIndividual types sum to more than all types because coinfections were counted in each type, but only included as single cases in counts of all types.
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/article-abstract/222/1/9/5815743 by guest on 05 August 2020
12 • jid 2020:222 (1 july) • Monto et al
in children younger than 5 years and adults older than 50 years 
were most likely to be classified as severe. In age-adjusted mul-
tinomial regression models (Table 2), 229E was associated with 
significantly higher odds of severe illness (versus mild) com-
pared to the 3 other HCoV types (odds ratio [OR], 1.82; 95% 
CI, 1.01–3.27). On the other hand, NL63 was associated with 
significantly lower odds of severe illness (versus mild) com-
pared to the other 3 types (OR, 0.59; 95% CI, .35–.99).
Household Transmission
Households present an ideal setting for determining the trans-
mission characteristics of respiratory viruses. Of the 993 
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Figure 1. Counts of human coronavirus (HCoV) infections over 8 study years by type and month of illness onset: Household Influenza Vaccine Evaluation Study 2010–2018.
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HCoVs identified, 260 occurred within 14 days of exposure to a 
household contact infected with the same type. The secondary 
attack risk was 7.2% for 229E, 8.6% for HKU1, 10.6% for OC43, 
and 12.6% for NL63. The average serial interval between the 
onset of illness in the household index case and onset of illness 
in secondary cases was similar across HCoV types (3.2 days for 
NL63 and HKU1, 3.3 days for OC43, and 3.6 days for 229E). 
Consistent with overall patterns of incidence by age (Figure 3), 
index cases were most frequently children, with the exception 
of 229E where adults aged 18 to 49 years were responsible for 
nearly half of the household introductions (Table 3).
DISCUSSION
While HCoVs have been recognized for many years to be a 
cause of common respiratory illnesses, documentation of their 
involvement has lagged behind that of other agents, such as 
the rhinoviruses; this includes frequency of infection, illnesses 
produced, and transmission characteristics. We might not even 
know about the existence of the 2 most recently identified vir-
uses, NL63 and HKU1, if attention had not been directed to 
HCoV following the occurrence of SARS. The development of 
the RT-PCR test and the inclusion of the 4 types of HCoV in 
multiplex clinical testing panels, mainly used in severe illnesses 
such as pneumonia, have resulted in numerous reports of the 
involvement of these viruses in hospitalizations. While studies 
of hospitalized patients have established the role of HCoV in 
causing lower respiratory illness and the global circulation of 
these viruses, they are unable to shed light on the frequency or 
seasonality of these viruses in the broader community. There 
are a few exceptions that have followed HCoV infections over 
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Figure 2. Incidence per 100 person-years of human coronavirus (HCoV) infections by type over 8 study years: Household Influenza Vaccine Evaluation Study 2010–2018. 
Error bars represent 95% confidence intervals.
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Figure 3. Incidence per 100 person-years of human coronavirus (HCoV) infections by type and age group over 8 study years: Household Influenza Vaccine Evaluation Study 
2010–2018. Error bars represent 95% confidence intervals.
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longer periods, often in special population groups. In partic-
ular, a recent study covered 9  years of Norwegian children 
hospitalized with respiratory infection and found that corona-
viruses were involved in 9.1% of episodes [26]. The highest fre-
quencies were in young children, similar to the infection rates 
demonstrated in the current study; also identical to the current 
study was the frequency of types involved, with OC43 the most 
common and 229E the least. While the authors did not empha-
size seasonality, it was clear that most of the infections occurred 
in the winter months.
The regular appearance of all types of coronaviruses in the 
same months with minimal circulation in the summer was a 
clear finding of this study. Unlike the influenza viruses, which 
peak at different times during the colder season from year to 
year, and even the rhinoviruses, which are most common in 
the autumn and spring but are present year round, the corona-
viruses are sharply seasonal with little spread after May until 
November or December. Our findings, on a larger scale, expand 
on the results of a 2-year study in childcare attendees suggesting 
a similar seasonal pattern [27]. It is of interest that the SARS 
coronavirus outbreaks occurred during the same time period, 
with the end of global outbreaks in the period of May–June 
2003 [28]. Whether such a timetable applies to the current cir-
culation of SARS-CoV-2 is impossible to determine at this time.
Another notable finding in this community study was the 
fact that, in those older than 4 years, HCoV infection rates were 
relatively consistent. Most agents causing lower respiratory in-
fections typically have falling incidence with increasing age, 
sometimes with an increase in young adults [29]. However, it 
is clear that like other respiratory viruses, HCoV infects people 
of all ages and infection only produces relative immunity. The 
type-specificity of the protection is also not completely clear, 
although frequent cocirculation of types and codetection 
within individuals suggests that protection is likely not highly 
cross-reactive. As with SARS and MERS, SARS-CoV-2 has 
most frequently infected adults to date [30]. Whether the rela-
tive sparing of children has largely been driven by contact and 
exposure patterns or other factors remains unclear. However, 
the frequency of infection in adults suggests that there is likely 
little cross-protective immunity from prior seasonal HCoV 
infection.
The MERS coronavirus is limited in its potential for human 
to human transmission except in the nosocomial setting 
[11]. Although the SARS coronavirus more effectively trans-
mitted human to human, transmission was interrupted by 
public health interventions [31]. The seasonal HCoV viruses 
are clearly different in their transmission characteristics given 
their continued seasonal circulation year after year. The serial 
interval between cases and the secondary infection risk in the 
HIVE cohort was similar to that previously found for A(H3N2) 
[32]. The secondary attack rates in the current study may reflect 
the relatively small household structure found in our region. 
A longitudinal study in Kenya found overall attack rates as high 
as 34.0% over 1 season in a study of households of sizes ranging 
up to 37 members [33].
The transition from pandemic to seasonal circulation is 
well established for influenza, wherein, following an influenza 
pandemic, the novel virus becomes the new seasonal virus, 
replacing the previous A  subtype [34]. The 4 current HCoVs 
have been circulating for decades, and it is unclear how they in-
itially emerged or whether they replaced previously circulating 
viruses [35]. Contrary to influenza, MERS and SARS have not 
become a fixed presence in seasonal respiratory illness circu-
lation on a global scale. Only time will tell if SARS-CoV-2 will 
become a continuing presence in the seasonal HCoV landscape, 
continue with limited circulation as with MERS, or, like SARS, 
disappear from humans altogether.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
Table 3. Household Index Casesa by Human Coronavirus (HCoV) Type and 
Age Group
 
HCoV Type, No. (Column %)
229E HKU1 NL63 OC43
Age group, y     
 0–5 13 (11.5) 38 (26.8) 45 (20.7) 82 (31.2)
 6–11 21 (18.6) 35 (25.4) 78 (36.9) 65 (24.7)
 12–17 16 (14.2) 9 (6.3) 24 (11.1) 24 (9.1)
 18–49 54 (47.8) 56 (39.4) 64 (29.5) 83 (31.6)
 ≥50 9 (8.0) 3 (2.1) 6 (2.8) 9 (3.4)
aOnly index cases from the first introduction of each coronavirus type to a household per 
season are included.
Table 2. Odd Ratios and 95% Confidence Intervals From Multinomial 
Logistic Regression Models Predicting Illness Severity From Human 
Coronavirus (HCoV) Type and Age Group
 
Severity Group, Odds Ratio (95% Confidence Interval)a
Mild Moderate Severe
HCoV type    
 229E Ref 1.51 (1.00–2.29) 1.82 (1.01–3.27)
 HKU1 Ref 1.13 (.77–1.66) 1.51 (.88–2.59)
 NL63 Ref 0.88 (.65–1.20) 0.59 (.35–.99)
 OC43 Ref 0.84 (.62–1.13) 0.87 (.55–1.37)
Age group, y    
 0–5 Ref 1.46 (1.04–2.04) 2.06 (1.27–3.33)
 6–11 Ref 1.53 (1.11–2.11) 1.02 (.60–1.72)
 12–17 Ref 0.99 (.62–1.61) 0.71 (.31–1.62)
 18–49 Ref 0.55 (.40–.74) 0.59 (.37–.94)
 ≥50 Ref 0.63 (.24–1.61) 1.23 (.40–3.80)
aOdds ratios are relative to all other groups within category (ie, 229E vs not, 0–5 y vs not).
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